You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Sangamo’s ST-920 demonstrates evidence of clinical benefit

Sangamo Therapeutics – a company focused on genomic medicine – has announced positive data relating to its phase 1/2 STAAR study of isaralgagene civaparvovec.